Compare Novo Nordisk A/S (NVO) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ON Holding AG — how do they compare? Novo Nordisk A/S trades at $38.64 (market cap $165.31B), while ON Holding AG trades at $35.09 (market cap $11.38B). The key difference: Novo Nordisk A/S is far larger — about 14.5× ON Holding AG's market cap, and Novo Nordisk A/S pays a 4.71% dividend while ON Holding AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and ON Holding AG for 22 Days on average.
| NVO | ONON | |
|---|---|---|
Market Cap | $165.31B | $11.38B |
Volume | 11,432,838 | 13,732,872 |
Sector | Health | Consumer Cyclical |
52-Week High | $63.98 | $50.63 |
52-Week Low | $35.29 | $26.76 |
Typical Hold Time | 116 Days | 22 Days |
Enterprise Value | $179.56B | $10.54B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
ONON stock trades at $35.09, up 5.63% with strong bullish momentum. The company demonstrates robust fundamentals with 64.82% gross margins and consistent earnings beats, including Q2 2026 EPS of $0.44 versus $0.42 expected. Recent investor day announcements of a $1 billion buyback program and ambitious 2029 targets have fueled positive sentiment. Technical indicators show bullish moving averages but overbought RSI conditions.
Outlook remains positive with analyst consensus at $42.26 target (20% upside) and 74% buy ratings. Key opportunities include premium store expansion and new sports categories, while risks involve execution on growth targets and competitive pressures in athletic footwear. The stock's current valuation at 24x P/E reflects growth expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
